Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Canopy Growth CorporationNASDAQ: CGC

Net Income · Q4 FY2025 · quarter ended Mar 2026

Net income declines year over year

Q4 FY2025 net income of CA$157.12M (cash outflow) fell 29.1% year over year, ahead of the -52.6% change in trailing-twelve-month net income. Sequentially, it rose 82.8% from the prior quarter. Over 3 fiscal years it compounded at -50.8% a year.

Context

  • Net income amounted to 75.8% of revenue in FY2025, down 148.8 pp from a year earlier.
  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 5 analysts of -CA$47.11M (-87.1%) for the fiscal year ending Mar 2027, a slowdown from the -39.3% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$157.12M+82.8% QoQ
Last fiscal yearMar 2026
-CA$366.64M-39.3% YoY
LTMMar 2026
-CA$286.21M-52.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-29.1%-57.7%-28.6 pp
1 year-39.3%-87.1%-47.8 pp
3-year CAGR-50.8%-58.9%-8.1 pp
5-year CAGR-46.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

CAD · from the cash flow

Latest · FY2025
(366.64M) CAD
Year-over-year change
+39.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -52.6% is the 7th highest of 9, against a peer median of -26.3%.
  • Net income amounts to 91.6% of revenue for CGC, versus a peer median of 61.3%.
CGC Competitors
Net Income for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGCCanopy Growth CorporationLTM Mar 2026CA$286.21M CAD-52.6%-50.8%91.6%
LYELLyell Immunopharma, Inc.LTM Mar 2026$246.41M USD-26.3%+14.4%794858.1%
DHDefinitive Healthcare Corp.LTM Mar 2026$182.83M USD-71.5%+107.7%76.7%
CABACabaletta Bio, Inc.LTM Mar 2026$175.43M USD+38.4%+46.9%—
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$165.86M USD+628.0%-48.4%45.9%
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M USD+26.6%+26.6%871.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M USD-46.5%-9.3%832.6%
ACBAurora Cannabis Inc.LTM Mar 2026CA$58.58M CAD-507.7%-39.5%18.8%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$34.09M USD—-30.8%25.2%
TKNOAlpha Teknova, Inc.LTM Mar 2026$17.17M USD-26.3%-28.6%41.1%
Peer median (excluding CGC) —-26.3%-9.3%61.3%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Net Income(258.91M)(3.08B)(483.68M)(604.14M)(366.64M)
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
Deferred Income Tax(8.95M)(5.73M)12.33M7.14M0
Stock-Based Compensation46.69M25.32M14.18M(4.21M)5.95M
Change in Working Capital205M58.97M3.97M(31.97M)20.68M
Accounts Receivables16.15M6.24M(3.75M)(4.49M)25.69M
Inventory204.22M68.44M1.03M(17.72M)3.71M
Accounts Payables00000
Other Working Capital(15.37M)(15.71M)6.68M(9.77M)(8.72M)
Other Non-Cash Items(640.58M)2.36B118.08M424.3M200.17M
Operating Cash Flow(545.81M)(557.55M)(281.95M)(165.75M)(88.98M)
Capital Expenditures(48.11M)(10.45M)(4M)(11.28M)(7.44M)
Acquisitions (Net)103.2M14.93M(955K)(6.97M)0
Purchases of Investments(379.41M)(67.15M)(347K)(95.34M)0
Sales of Investments546.01M502.59M78.55M16.43M26.5M
Other Investing Activities(2.3M)(7.88M)167.79M48.9M(48.83M)
Investing Cash Flow230.82M433.38M241.59M(47.79M)(29.77M)
Debt Repayment(50.76M)16.98M(509.78M)(220.78M)(24.62M)
Common Stock Issued2.7M1.05M81.06M385.39M374.17M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.53M(37.72M)(36.34M)(15.96M)114.02M
Financing Cash Flow(45.53M)(19.69M)(465.06M)148.66M463.57M
Effect of Forex Changes(18.12M)44.86M(1.29M)8.39M5.05M
Net Change in Cash(378.65M)(99M)(506.71M)(56.49M)349.86M
Free Cash Flow(593.92M)(568M)(285.95M)(177.03M)(96.42M)

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.